江西医药
江西醫藥
강서의약
JIANGXI MEDICAL JOURNAL
2014年
8期
659-661
,共3页
郭经华%聂祥碧%杨春丽%王曾庚
郭經華%聶祥碧%楊春麗%王曾庚
곽경화%섭상벽%양춘려%왕증경
脓毒症%低分子肝素%T淋巴细胞亚群%B淋巴细胞
膿毒癥%低分子肝素%T淋巴細胞亞群%B淋巴細胞
농독증%저분자간소%T림파세포아군%B림파세포
Sepsis%Low molecular heparin%T lymphocyte subsets%B lymphocyte
目的评价低分子肝素对脓毒症患者免疫功能及预后的影响。方法选取2013年1月至2013年6月入院的脓毒症患者40例,分为低分子肝素组及对照组,于治疗前及治疗第3、7d使用流式细胞仪检测脓毒症患者使用低分子肝素前后T淋巴细胞亚群、NK细胞、B淋巴细胞的变化,同时统计患者APACHEⅡ评分、28d病死率、ICU住院时间。比较两组患者T淋巴细胞亚群、B淋巴细胞、NK细胞变化情况及与APACHEⅡ评分及28d病死率、ICU住院时间变化。结果两组患者的T淋巴细胞亚群、B淋巴细胞、NK细胞随积极治疗后逐步升高,但两组间比较无统计学差异(P>0.05)。组间比较APACHEⅡ评分无统计学差异(P>0.05),但低分子肝素组APACHEⅡ评分下降明显优于对照组,且低分子肝素组治疗前后APACHEⅡ评分改变有统计学差异(P<0.05)。低分子肝素组患者住ICU时间、病死率均比对照组低,但两组间比较差异均无显著性(P>0.05)。结论低分子肝素用于脓毒症患者的治疗能改善患者的APACHEⅡ评分、28d病死率、ICU住院时间,但无统计学差异,对免疫功能的影响有待进一步的研究。<br> Department of Critical Care Medicine,People’s Hospital of Jiangxi Province,Nanchang,Jiangxi Province 330006.
目的評價低分子肝素對膿毒癥患者免疫功能及預後的影響。方法選取2013年1月至2013年6月入院的膿毒癥患者40例,分為低分子肝素組及對照組,于治療前及治療第3、7d使用流式細胞儀檢測膿毒癥患者使用低分子肝素前後T淋巴細胞亞群、NK細胞、B淋巴細胞的變化,同時統計患者APACHEⅡ評分、28d病死率、ICU住院時間。比較兩組患者T淋巴細胞亞群、B淋巴細胞、NK細胞變化情況及與APACHEⅡ評分及28d病死率、ICU住院時間變化。結果兩組患者的T淋巴細胞亞群、B淋巴細胞、NK細胞隨積極治療後逐步升高,但兩組間比較無統計學差異(P>0.05)。組間比較APACHEⅡ評分無統計學差異(P>0.05),但低分子肝素組APACHEⅡ評分下降明顯優于對照組,且低分子肝素組治療前後APACHEⅡ評分改變有統計學差異(P<0.05)。低分子肝素組患者住ICU時間、病死率均比對照組低,但兩組間比較差異均無顯著性(P>0.05)。結論低分子肝素用于膿毒癥患者的治療能改善患者的APACHEⅡ評分、28d病死率、ICU住院時間,但無統計學差異,對免疫功能的影響有待進一步的研究。<br> Department of Critical Care Medicine,People’s Hospital of Jiangxi Province,Nanchang,Jiangxi Province 330006.
목적평개저분자간소대농독증환자면역공능급예후적영향。방법선취2013년1월지2013년6월입원적농독증환자40례,분위저분자간소조급대조조,우치료전급치료제3、7d사용류식세포의검측농독증환자사용저분자간소전후T림파세포아군、NK세포、B림파세포적변화,동시통계환자APACHEⅡ평분、28d병사솔、ICU주원시간。비교량조환자T림파세포아군、B림파세포、NK세포변화정황급여APACHEⅡ평분급28d병사솔、ICU주원시간변화。결과량조환자적T림파세포아군、B림파세포、NK세포수적겁치료후축보승고,단량조간비교무통계학차이(P>0.05)。조간비교APACHEⅡ평분무통계학차이(P>0.05),단저분자간소조APACHEⅡ평분하강명현우우대조조,차저분자간소조치료전후APACHEⅡ평분개변유통계학차이(P<0.05)。저분자간소조환자주ICU시간、병사솔균비대조조저,단량조간비교차이균무현저성(P>0.05)。결론저분자간소용우농독증환자적치료능개선환자적APACHEⅡ평분、28d병사솔、ICU주원시간,단무통계학차이,대면역공능적영향유대진일보적연구。<br> Department of Critical Care Medicine,People’s Hospital of Jiangxi Province,Nanchang,Jiangxi Province 330006.
Objective To evaluate the effect of low molecular heparin on immune function and prognosis of patients with sep-sis. Method 40 hospitalized patients with sepsis from Jan 2013 to June 2013,were divided into low molecular heparin group and control group,before treatment and at third and seventh day using flow cytometry to test the change of T lymphocyte subsets,NK cells,B lymphocytes before and after using low molecular weight heparin of patients with sepsis. and at the same time make statis-tics which were APACHE Ⅱscore,28d mortality and length of time in the ICU. To compare two group patients’ change of T lym-phocyte subsets,B lymphocytes and NK cells,and the change of APACHE Ⅱscore and 28d mortality, length of hospitalized time in the ICU. Results T lymphocyte subsets,B lymphocytes,NK cells of two groups patients with active treatment were gradually increased,but the two groups had no statistical difference(P>0.05). Comparison between groups of APACHE Ⅱ score were no sig-nificant difference (P>0.05),but the low molecular heparin group APACHE II score were lower than that of the control group,and the change of APACHE Ⅱ score of low molecular heparin group before and after treatment was statistically significant difference (P<0.05). Length of hospitalized time in the ICU and mortality of low molecular heparin group were lower than that of control group,but there was no significant difference between two groups(P>0.05). Conclusion The treatment of low molecular heparin on patients with sepsis can improve the patient's APACHE Ⅱscore,28d mortality,length of hospitalized time in the ICU,but there is no significant difference,the effects on the immune function are needed to do further study.